Regenerative medicine specialistย CollPlantย has partnered withย BICOย firmย CELLINKย in an effort to ramp up its production of 3D bioprinted breast implants.ย 

Currently undergoing preclinical trials, CollPlantโ€™s bioprinted grafts are designed to degrade over time and be replaced by native tissues, in a treatment that could prove much safer than traditional augmentation procedures. In an effort to scale the production of these grafts, the firm has now begun working with CELLINK, in a partnership with the potential to unlock a market it values at $2.8 billion.ย 

Read the full article at 3dprintingindustry.com